The Effect of Curcuma and Garcinia Peel on Rat PPARα Gene Expression Induced by High-Fat Diet

Diana Krisanti Jasaputra, Hoo Yumilia, Julia Windi Gunadi, Ronny Lesmana, Andieni Faqhira Permadi

Abstract


High levels of fat in the blood are a risk factor for nonalcoholic steatohepatitis liver disease. Indonesian medicinal plants that can decrease blood fat levels are turmeric and mangosteen peel. One of the mechanisms of blood fat-lowering drugs is to increase the expression of the PPARα gene. The purpose of this study was to assess the effect of turmeric and mangosteen peel on the expression of the PPARα gene in the rat liver induced by a high-fat diet. This research was conducted at Maranatha Biomedical Research Laboratory in February–October 2021, using male Wistar rats that were divided into 5 groups (n=5): negative control groups (no treatment), positive control groups (high-fat diet), turmeric, mangosteen, and fenofibrate groups, that was given high-fat diet continued by ethanol extract of turmeric, ethanol extract of mangosteen peel, and fenofibrate. At the end of the study, the animals were terminated, and the liver was extracted for RNA extraction and semi-quantitative PCR. The results showed that there was an increase in PPARα gene expression in the turmeric group and fenofibrate group, which were significantly different from the positive control group that received a high-fat diet (p<0.05) and between the fenofibrate group compared to negative controls that received standard chow diet (p<0.05). In conclusion, turmeric and fenofibrate are suggested to increase the expression of the PPARα gene in the liver induced by a high-fat diet.

Keywords


Mangosteen peel; PPARα; turmeric

Full Text:

PDF

References


Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136:e1–23.

Ahn CH, Choi SH. New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J. 2015;39(2):87–94.

Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68.

Chuah LO, Ho WY, Beh BK, Yeap SK. Updates on antiobesity effect of Garcinia origin (−)-HCA. Evid Based Complement Alternat Med. 2013;2013:751658.

Larissa L, Martioso P, Jasaputra D. Activity of javanese ginger, turmeric, garlic, and pomegranate flower on LDL-C and total-C on dyslipidemia model rats. GMHC. 2021;9(2):143–9

Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009;60(3):151–9.

Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. Int J Mol Sci. 2020;21(6):2061.

Tian Y, Yang Y, Zhang X, Nakajima T, Tanaka N, Sugiyama E, et al. Age-dependent PPARα activation induces hepatic sulfatide accumulation in transgenic mice carrying the hepatitis C virus core gene. Glycoconj J. 2016;33(6):927–36.

Rigano D, Sirignano C, Taglialatela-Scafati O. The potential of natural products for targeting PPARα. Acta Pharm Sin B. 2017;7(4):427–38.

Omosa LK, Midiwo JO, Kuete V. Curcuma longa. In: Kuete V, editor. Medicinal spices and vegetables from Africa: therapeutic potential against metabolic, inflammatory, infectious and systemic diseases. Cambridge: Academic Press; 2017. p. 425–35.

Razila A, Ramli S. Optimisation of mangosteen peel extracts (Garcinia mangostana L.) on total flavonoid content using response surface methodology (RSM) and its antioxidant activities. In: Zahid MNO, Sani ASA, Yasin MRM, Ismail Z, Lah NAC, Turan FH, editors. Recent trends in manufacturing and materials towards industry 4.0: selected articles from iM3F 2020, Malaysia. Singapore: Springer Nature Singapore; 2021. p. 343–61.

Black MH, Watanabe RM, Trigo E, Takayanagi M, Lawrence JM, Buchanan TA, et al. High-fat diet is associated with obesity-mediated insulin resistance and β-cell dysfunction in Mexican Americans. J Nutr. 2013;143(4):479–85.

Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317(5):R733–45.

Duan Y, Zeng L, Zheng C, Song B, Li F, Kong X, et al. Inflammatory links between high-fat diets and diseases. Front Immunol. 2018;9:2649.

Contreras A V, Torres N, Tovar AR. PPAR-α is a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr. 2013;4(4):439–52.

Patsouris D, Reddy JK, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147(3):1508–16.

Trusda S, Purbaningsih W, Budiman B, Fitriadi S. Characteristics of patients with type 2 diabetes mellitus in Al-Ihsan Regional General Hospital. GMHC. 2021;9(2):150–7.

Kim YH, Jang WG, Oh SH, Kim JW, Lee MN, Song JH, et al. Fenofibrate induces PPARα and BMP2 expression to stimulate osteoblast differentiation. Biochem Biophys Res Commun. 2019;520(2):459–65.

Ruscica M, Busnelli M, Runfola E, Corsini A, Sirtori CR. Impact of PPAR-alpha polymorphisms—the case of metabolic disorders and atherosclerosis. Int J Mol Sci. 2019;20(18):4378.

Kimura O, Kondo Y, Shimosegawa T. PPAR could contribute to the pathogenesis of hepatocellular carcinoma. PPAR Res. 2012;2012:574180.

Ouk T, Gautier S, Pétrault M, Montaigne D, Maréchal X, Masse I, et al. Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab. 2014;34(3):542–51.

Majeed Y, Upadhyay R, Alhousseiny S, Taha T, Musthak A, Shaheen Y, et al. Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. Sci Rep. 2019;9(1):6316.

Montagner A, Polizzi A, Fouché E, Ducheix S, Lippi Y, Lasserre F, et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016;65(7):1202–14.

Nikam A, Patankar J V, Somlapura M, Lahiri P, Sachdev V, Kratky D, et al. The PPARα agonist fenofibrate prevents formation of protein aggregates (Mallory-Denk bodies) in a murine model of steatohepatitis-like hepatotoxicity. Sci Rep. 2018;8(1):12964.

Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2015;62(3):720–33.

Todisco S, Santarsiero A, Convertini P, Stefano G De, Gilio M, Iacobazzi V, et al. PPAR Alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Biology (Basel). 2022;11(5):792.




DOI: https://doi.org/10.29313/gmhc.v11i3.10993

pISSN 2301-9123 | eISSN 2460-5441


Visitor since 19 October 2016: 


Free counters!


Global Medical and Health Communication is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.